Bristol Myers buys Nvidia's latest AI computing system for drug research

Bristol Myers Squibb has announced it is acquiring Nvidia’s latest AI computing system to enhance its drug discovery and development processes. The deal involves the purchase of the Nvidia DGX SuperPOD based on the company’s newly introduced Vera Rubin architecture. This marks the first time a life sciences firm has acquired such a system, according to the pharmaceutical giant. The move underscores the growing reliance on advanced computational power within the biopharmaceutical industry to accelerate drug innovation. The acquisition follows Bristol Myers' previous purchase of a smaller SuperPOD system from Nvidia, which is estimated to be two to three generations behind the new Vera Rubin-based model. Financial details of the transaction were not revealed, though executives emphasized the strategic importance of upgrading their AI infrastructure. Nvidia introduced the Vera Rubin architecture earlier this year as the successor to its existing AI computing systems. The new architecture promises enhanced performance and efficiency, aligning with Bristol Myers’ goal of scaling up its AI-driven research initiatives. According to company officials, the increased computational power will enable them to evaluate significantly more potential drug candidates during the early stages of development. Robert Plenge, Bristol Myers’ chief research officer, noted that the new system would allow the company to process several dozen potential drug candidates instead of just a handful. He explained that AI tools have already reduced the time required to develop medicines for clinical testing by 20 to 30 percent, with the possibility of reaching 50 percent in the future. One example cited by Plenge is an experimental treatment for sickle cell disease currently in early clinical development, which he stated might not have been identified without AI-assisted research. Greg Meyers, the company’s chief digital and technology officer, highlighted that the decision to invest in the new system was partly driven by rising computational demands as Bristol Myers expands its use of AI across its research operations. AI is being integrated into both small-molecule and large-molecule drug development programs. Meyers also pointed out the improved energy efficiency of the new system, which is crucial given the increasing costs of electricity. He likened the cost savings to having ten times more computing power per unit of energy consumed. The integration of AI into drug discovery represents a broader trend among pharmaceutical companies seeking to streamline the often lengthy and costly process of bringing new treatments to market. By leveraging AI, firms aim to identify viable drug targets more quickly and increase the likelihood of success in later-stage clinical trials. This shift reflects a fundamental change in how modern drug development is approached, with computational power playing an ever-increasing role. Bristol Myers’ continued investment in cutting-edge AI technologies positions it as a leader in applying artificial intelligence to pharmaceutical innovation. As the company scales its AI capabilities, it aims to maintain a competitive edge in developing novel therapies while addressing challenges related to resource consumption and operational efficiency. The deployment of the new system is expected to further solidify the company’s commitment to advancing medical science through technological advancement.